<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068974</url>
  </required_header>
  <id_info>
    <org_study_id>OBU-OvaC-IIT-SHR1210-APA</org_study_id>
    <nct_id>NCT04068974</nct_id>
  </id_info>
  <brief_title>Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer</brief_title>
  <official_title>Camrelizumab Combined With Apatinib for Recurrent Platinum-resistant Ovarian Cancer: a Phase 2 Single-arm Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intend to improve the progression-free survial of the recurrent
      paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined
      with apatinib.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to two years</time_frame>
    <description>The proportion of participants with tumor size reduction of a predefined amount and for a minimum time period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to two years</time_frame>
    <description>The time from treatment until objective tumor progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Up to two years</time_frame>
    <description>The proportion of patients with complete response, partial response or keep stable diease after accept treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to two years</time_frame>
    <description>The time from firstly complete response or partly response to progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to two years</time_frame>
    <description>The quantity and degree of adverse event and serious adverse event from</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Recurrent Platinum-resistant Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab (SHR-1210)</intervention_name>
    <description>Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 [PD-1]). Monoclonal antibodies like SHR-1210 that can block this pathway.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with recurrent -resistant epithelial ovarian cancer, fallopian tube cancer
             and primary peritoneal cancer previously received twice or more platinum chemotherapy
             before enrolment;

          2. Recurrence occurred within 6 months after the last platinum-containing chemotherapy
             and had experienced at least one platinum-sensitive recurrent in the past.;

          3. Aged 18-70 years;

          4. An Eastern Cooperative Oncology Group performance status of 0-2;

          5. According to the solid tumor efficacy evaluation standard (RECIST1.1) or i RECIST, at
             least one measurable lesion, with maximum diameter &gt; 1 cm and lymph node metastasis &gt;
             1.5 cm, and the target lesion is not suitable for surgical treatment; the target
             lesion has not received radiotherapy or recurred in the field of radiotherapy.

          6. Expected survival ≥ 4 months;

          7. The function of vital organs meets the following requirements： Hemoglobin≥80g/L;
             Absolute neutrophil count≥1.5*109/L；Platelets≥100

             *109/L; Creatinine≤1.5 times ULN; Urea nitrogen≤2.5 times ULN; Total Bilirubin≤ULN;
             ALT and AST ≤ 2.5 times ULN; Albumin≥25g/L; TSH≤ULN(if TSH is abnormal, normal T3 and
             T4 also can acceptable)

          8. The subject should be aware of the purpose of the study and the operations required by
             the study and volunteer to participate in the study before sign the informed consent
             form.

        Exclusion Criteria:

          1. Primary platinum refractory patients (first platinum-containing chemotherapy with
             recurrence within 6 months)

          2. Previously exposed to other anti-angiogenic small-molecule TKI drugs, such as
             pazopanib, sorafenib, regorafenib, cilnitraz, etc. or anti-angiogenic mAbs such as
             bevacizumab ; or had used an anti-PD-1 antibody, an anti-CTLA-4 antibody, TCR-T, CAR-T
             and other immune therapy; or 4 weeks before the first administration participated in
             any other clinical trials of anticancer drugs; or before the first dose Live
             attenuated vaccines are accepted within 4 weeks or during the study period.

          3. Target lesions observed received radiotherapy

          4. Other malignant tumors have occurred in the past 3 years..

          5. Immunosuppressive drugs used within 14 days prior to the first use of SHR-1210,
             excluding nasal and inhaled corticosteroids or physiological doses of systemic steroid
             hormones (ie, no more than 10 mg/day of turmeric or equivalent drug physiological
             dose) Other corticosteroids).

          6. Late-stage patients with symptomatic, disseminated to visceral, short-term risk of
             life-threatening complications (including uncontrolled large amounts of exudate
             [thoracic, pericardium, abdominal cavity], pulmonary lymphangitis, and more than 30%
             liver involvement patients).

          7. Any active autoimmune diseases or a history of autoimmune diseases (including but not
             limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,
             hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, decreased
             thyroid function; subjects with vitiligo or complete remission asthma in childhood and
             without any intervention, all above can be included; asthma requiring medical
             intervention for bronchodilators should be excluded).

        8 Metastatic foci of the central nervous system have significant symptoms, such as
        headache, cerebral edema and blurred vision 9. CT or MRI showed tumor lesion 5mm away from
        the great blood vessel, or tumor invading the local great blood vessel, or accompanied by
        tumor thrombus formation of the great vein (inferior vena cava of iliac vessel, superior
        vena cava of pulmonary static vein) 10. Uncontrollable hypertension (systolic blood
        pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, despite with the optimal medical
        treatment.

        11. Grade II or higher myocardial ischemia, myocardial infarction or poor control
        arrhythmia (including male with QTc interval ≥ 450ms, or female with QTc interval≥ 470ms).
        According to NYHA criteria, grade III to IV cardiac insufficiency, or cardiac color Doppler
        ultrasound examination showed left ventricular ejection fraction (LVEF) &lt;50%; myocardial
        infarction occurred within 6 months before enrollment, New York Heart Association Level II
        or above failure, uncontrolled angina, uncontrolled severe ventricular arrhythmia,
        pericardial disease with clinically significant, or electrocardiogram suggesting acute
        ischemia or abnormal active conduction system.

        12, Abnormal coagulation (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN + 4 seconds or APTT &gt;
        1.5ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy.

        13. Half of a teaspoons (2.5 ml) or more hemoptysis was found within the first 2 months or
        there were significant clinical bleeding symptoms or clearly propensity bleeding within 3
        months before participant in the study, such as gastrointestinal bleeding, hemorrhagic
        gastric ulcer, fecal occult blood ++ or above in baseline or vasculitis; artery or venous
        thrombosis events within 6 months prior to the study, such as cerebrovascular accidents
        (Including transient ischemic attacks, cerebral hemorrhage, cerebral infarction, deep vein
        thrombosis and pulmonary embolism.

        14. Severe infections within 4 weeks prior to accept medication (eg, intravenous infusion
        of antibiotics, antifungal or antiviral drugs), or unexplained fever during screening/first
        administration &gt;38.5 °C 15. Those who have a history of psychotropic drug abuse and are
        unable to quit or have mental disorders.

        16. Major surgical procedures were performed within 4 weeks before the first
        administration. Or open wounds or fractures.

        17. There are obvious factors affecting oral drug absorption, such as inability to swallow,
        chronic diarrhea and intestinal obstruction. Or sinus or perforation of empty organs within
        6 months.

        18. Routine urine test indicated that urinary protein (++) or more, confirmed urinary
        protein (&gt;1.0 g) within 24 hours.

        19. Patients with a history of allergy may be potentially allergic or intolerant to
        Apatinib and biological agents SHR-1210.

        20. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency
        syndrome (AIDS), active hepatitis B (HBV DNA (&gt; 500 IU/ml), hepatitis C (hepatitis C
        antibody positive, and HCV-RNA higher than the lower limit of the analysis method) or
        co-infection with hepatitis B and hepatitis C.

        21. There is any situation that may damage the subject or cause the subject to fail to meet
        or implement the research requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pan lingya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pan Lingya</last_name>
    <phone>010-69156204</phone>
    <email>Panly@pumch.cn</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lingya Pan</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Recurrent Platinum-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

